Navigation Links
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Date:4/17/2008

egenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and CETHRIN, the prospects of the Company's CNS and regenerative therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertain
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 15, 2014  The Government of Ghana ... Blood Fund (GBF) and Terumo BCT to respond to the emerging ... as provide long-term health system capacity to the citizens of ... The Ghanaian Ebola Readiness and Resilience Initiative (GERRI) is a multi-agency ... preparations for the possible arrival of the Ebola epidemic , ...
(Date:12/13/2014)... December 12, 2014 ... the addition of the  "Global Catheters Market ... Global Trends, Company Profiles, Analysis, Segmentation and ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... up of medical grade material such as ...
(Date:12/13/2014)... 12, 2014 Research ... addition of the  "Global Capnography Market 2015-2019" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Capnography is the ... respiratory gasses during the integral part of ... information about CO2 production, alveolar ventilation, and ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Global Catheters Market (Product Types and Geography) - Forecast to 2020 2Global Catheters Market (Product Types and Geography) - Forecast to 2020 3Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 2Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 3
... KemPharm, Inc. today announced that KP106, its clinical candidate ... developed in an oral film dosage form pursuant to ... the development, commercialization and manufacture of KP106.   ... of d -amphetamine, and was identified utilizing KemPharm,s ...
... Mass., April 25, 2011 SynapDx Corporation announced ... directors. Thomas Mac Mahon was President and ... Management Committees of Laboratory Corporation of America (LabCorp) from January ... to LabCorp, Mr. Mac Mahon was Senior Vice President of ...
Cached Medicine Technology:KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD 2KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD 3KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Crestor Will Remain the Clinical Gold Standard Drug Through 2016, ... to a New Report ... Resources, one of the,world,s leading research and advisory firms focusing ... high-density lipoprotein,cholesterol and has a lower discontinuation rate than that ...
... Medical,Equipment, Inc. (OTC: SHOM) announced today that the ... Industry statistics,suggest a very favorable market into the ... U.S. Bureau of Labor Statistics published in,the November ... new and,replacement nurses will be needed by 2016. ...
... 245-Bed Hospital To Better Track Expensive Assets and ... InfoLogix, Inc.,(Nasdaq: IFLG ), a leading ... tracking solutions for the healthcare and,commercial industries, announced ... Center of Lebanon, TN, to deploy its advanced,HealthTrax(TM) ...
... REDWOOD CITY, Calif., July 29 Genomic Health,Inc. (Nasdaq: ... host a conference,call and webcast on Tuesday, August 5, ... quarter 2008 financial results. The call and webcast,will follow ... close., Conference Call Details, To access the ...
... D sufficiency, new, antimicrobial-susceptibility system/panels for MRSA and other ... and enhanced automated laboratory systems, ... poisoning will also be on view, WASHINGTON, July 29 ... Expo will see Magellan Biosciences, continued,emergence as a new leader ...
... Each summer, as temperature and,humidity rise, mold ... U.S.,population is sensitive to mold, and invisible mold ... infections, according to the,American College of Allergy, Asthma ... building materials. In nature, mold breaks,down decaying organic ...
Cached Medicine News:Health News:A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market 2Health News:Southern Home Medical's Encore Medical Staffing Division Poised to Benefit from Major Growth in Nursing Industry 2Health News:InfoLogix Selected by University Medical Center to Deploy Mobile Wireless Asset Tracking Solution 2Health News:InfoLogix Selected by University Medical Center to Deploy Mobile Wireless Asset Tracking Solution 3Health News:Genomic Health to Announce Second Quarter 2008 Financial Results and Host Conference Call on Tuesday, August 5, 2008 2Health News:Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo 2Health News:Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo 3Health News:Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo 4Health News:Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo 5Health News:Creating a Healthy Home Environment: Mold and Mildew Free 2
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
... the first High Frequency Desiccator with Cut. You ... of the unit is a high frequency desiccator, ... Aaron 900. The other half is a Bovie ... and coag capabilities plenty of power for ...
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
Medicine Products: